1. Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration.
- Author
-
Mehta, Neesurg, Fong, Rodney D, Wilson, Machelle, Moussa, Kareem, Emami-Naeini, Parisa, Moshiri, Ala, Yiu, Glenn, and Park, Susanna S
- Subjects
aflibercept ,age-related macular degeneration ,anti-VEGF ,brolucizumab ,intravitreal injection ,optical coherence tomography ,Clinical Research ,Eye Disease and Disorders of Vision ,Neurodegenerative ,Aging ,Macular Degeneration ,6.1 Pharmaceuticals ,Development of treatments and therapeutic interventions ,5.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Eye ,intravitreal injection ,optical coherence tomography ,Opthalmology and Optometry - Abstract
PurposeTo evaluate real-world experience using intravitreal brolucizumab (IVBr), alone or in combination with aflibercept, in eyes with neovascular age-related macular degeneration (nAMD) treated previously with other inhibitors of VEGF (anti-VEGF).MethodsThis was a retrospective study of all eyes with nAMD treated with IVBr on a treat-and-extend protocol at a single center. Best-corrected visual acuity (BCVA), optical coherence tomography (OCT) at baseline and final visit, and drug-related adverse events were analyzed. Eyes with recurrent macular fluid on IVBr every 8 weeks were treated with a combination therapy alternating between IVBr and aflibercept every month.ResultsAmong 52 eyes (40 patients) on IVBr, all had been previously treated with other anti-VEGF therapy, with 73% having persistent macular fluid. After a mean follow-up of 46.2±27.4 weeks on IVBr, the mean treatment interval for intravitreal therapy increased to 8.8±2.1 weeks on IVBr from a baseline of 6.1±3.1 weeks (p
- Published
- 2023